PickAlpha Evening Insights | 2026-03-05 - Market Wrap and Trades For Tomorrow
• Stocks closed steady as front-end yields and the dollar reacted to jobs and oil inventory news. • After hours: Marvell, Costco and Gap drove the earnings cluster with mixed beats and guidance shift
Market Wrap
Market Recap — Claims held steady while a surprise crude build and a cluster of corporate reports set the tone. Weekly initial jobless claims were unchanged at 213k and continuing claims rose, nudging front-end Treasuries and the dollar ($ZN=F, $DX=F). EIA reported a 3.5mn-barrel crude build that pressured oil-sensitive positions ($CL=F). Postmarket strength in Marvell ($MRVL) and Costco ($COST) contrasted with Gap’s ($GAP) cautious EPS guide and buyback announcement.
Intraday — At 08:30 ET the Labor Department showed initial claims steady at 213k and higher continuing claims, a datapoint that softened short-duration yields and lifted dollar volatility ($ZN=F, $DX=F); at 10:30 ET the EIA said commercial crude inventories rose 3.5mn barrels while gasoline drew 1.7mn and refinery utilization was 89.2%, pressuring energy pricing and related equities ($CL=F).
After Hours — Beginning ~16:00 ET Marvell reported fiscal Q4 revenue of $2.219bn and guided Q1 above consensus, boosting its stock on stronger AI-networking outlooks ($MRVL); Costco posted fiscal Q2 sales and adjusted comparable-sales beats, supporting retail sentiment ($COST); later Gap guided fiscal 2026 EPS roughly $2.20–$2.35, authorized a $1bn buyback and raised capex, a mix that left its stock reaction nuanced ($GAP).
Market Wrap and Trades For Tomorrow
1/3 Short $SPY — Intraday (0–1d) • Macro
Plan: If average hourly earnings print at or above 0.4% m/m, short $SPY at next regular-session open into day-1 close.
February payrolls are due March 6 with Reuters expecting +59k jobs and unemployment at 4.3%. Average hourly earnings are forecast to slow to +0.3% m/m after January’s +0.4% and 3.7% y/y. A wage print at or above 0.4% m/m would signal sticky labor inflation, likely tempering Fed rate-cut expectations and pressuring broad U.S. equities, favoring a tactical intraday short in $SPY.
Risk: Exit if $SPY closes higher on the day of the payrolls release despite wages. • Valid until 2026-03-12 23:59 ET
Trade credibility: actionability ★★★★☆ | timeliness ★★★★★ | clarity ★★★★☆
2/3 Long $BMY — Tactical (1–5d) • Policy
Plan: If FDA approves Sotyktu psoriatic-arthritis sNDA March 6, go long $BMY in first session after decision for next 1–3 sessions.
Bristol Myers Squibb faces a March 6 PDUFA date for Sotyktu’s psoriatic arthritis sNDA after positive POETYK PsA data, including Week 16 ACR20 of 54.2% vs 34.1% for placebo and Week 52 ACR20 of 63.1% with no new safety signals. Approval would add a new labeled indication, lifting Sotyktu sales expectations and improving BMY’s immunology revenue mix near term.
Risk: Exit if FDA issues a non-approval outcome or labels decision as delayed beyond March 6. • Valid until 2026-03-12 23:59 ET
Trade credibility: actionability ★★★★☆ | timeliness ★★★★☆ | clarity ★★★★☆
3/3 Long $MRVL — Tactical (1–5d) • Earnings
Plan: Go long $MRVL at next regular-session open and hold for the next 1–3 sessions.
Marvell reported fiscal Q4 revenue of $2.219 billion and non-GAAP EPS of $0.80, with data-center revenue up 21% to $1.65 billion. Fiscal Q1 revenue guidance of about $2.40 billion topped the $2.27 billion consensus, and management raised its fiscal 2027 revenue growth outlook to more than 30%. This AI-networking strength supports a tactical long as investors digest the higher growth path.
Risk: Exit if $MRVL closes below your entry price on the second full session after entry. • Valid until 2026-03-12 23:59 ET
Trade credibility: actionability ★★★★☆ | timeliness ★★★★☆ | clarity ★★★★☆